The following drug information is obtained from various newswires, published medical journal articles, and medical conference presentations.

Approval Status:

Approved January 1998

Specific Treatments:


Therapeutic Areas

General Information

Noritate (metronidazole cream) 1% has been approved as a topical rosacea therapy for the treatment of inflammatory lesions and erythema (facial redness) associated with the condition.

Clinical Results

Noritate has been shown to significantly reduce inflammatory lesions of rosacea in as little as four weeks with minimal skin dryness and irritation.